PortViewPortView
Veraxa Biotech Holding AG logo

Veraxa Biotech Holding AG (VRXA) Stock Analysis

NASDAQHealthcareBiotechnology

$1.38-1.43%
1-year price historyRange $1.35 – $24.79
52-week range$1.38
$1.27$27.36

What Veraxa Biotech Holding AG does

Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]

Key metrics

Market cap
$195.14M
P/E (TTM)
-2.38
EPS (TTM)
$-0.58
Beta
0.26
50-day avg
$1.99
200-day avg
$8.92
52-week high
$27.36
52-week low
$1.27
CEO
Christoph Antz

ETFs linked to VRXA

Broad-market and Healthcare sector ETFs an investor holding Veraxa Biotech Holding AG is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VRXA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze VRXA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Veraxa Biotech Holding AG?
Veraxa Biotech Holding AG trades under the ticker VRXA on NASDAQ.
Which exchange is VRXA listed on?
VRXA is listed on NASDAQ.
What sector does Veraxa Biotech Holding AG operate in?
Veraxa Biotech Holding AG is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze VRXA in a portfolio?
PortView shows VRXA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.